MichaelEMendelsohnMD

Summary

• Cardiovascular physician-scientist, research leader and business executive with broad experience in healthcare (cardiovascular and internal medicine, basic and clinical sciences, executive management). Founder and Executive Chairman of Cardurion Pharmaceuticals, a cardiovascular biotechnology company. Dr. Mendelsohn also serves currently as senior advisor and consultant to the head of R&D at Takeda Pharmaceuticals and as a Board Director of Foghorn Therapeutics and Broadview Ventures. From 2013-2017, Dr. Mendelsohn served as a venture partner at SV Health Investors.
  
  From 2010-2013, Dr. Mendelsohn served as SVP and Global Head of Cardiovascular Diseases, Merck & Co. Prior to Merck, Dr. Mendelsohn worked for 25 years as an academic cardiovascular physician-scientist in Boston. Dr. Mendelsohn received an undergraduate degree in Chemistry and English from Amherst College and his MD from Harvard Medical School (HMS) in 1982. From 1988-1993, he was an assistant professor of medicine on the faculty of HMS, a member of the BWH Cardiology Division and ran an independent, NIH-funded basic science laboratory focused on molecular cardiovascular biology. From 1993-2010, he moved to Tufts Medical Center, where served as the first executive director of the Molecular Cardiology Research Institute, In 2008, Dr. Mendelsohn was named Chief Scientific Officer at Tufts. In 2010, Dr. Mendelsohn was appointed senior vice president and global head of cardiovascular research at Merck Research Laboratories (MRL). He founded Cardurion Pharmaceuticals in 2017.